吉非替尼联合西黄丸治疗晚期非小细胞肺癌的疗效评价

目的 评价吉非替尼联合西黄丸治疗晚期非小细胞肺癌的临床疗效.方法 选取2015年9月至2018年12月我院收治的晚期非小细胞肺癌患者21例为研究对象,所有患者均接受吉非替尼联合西黄丸治疗,观察患者的近期疗效.结果 21例患者中,疾病稳定(SD)10例,部分缓解(PR)8例,疾病进展(DP)3例,完全缓解(CR)0例,疾病缓解率(DRR)38.09％(8/21),疾病控制率(DCR)85.71％(18/21).用药治疗后随访6～24个月,36例患者中死亡3例,无进展生存期(PFS)5～14(7.12±0.93)个月,总生存期(OS)6～24(10.23±1.10)个月.用药期间,出现恶心、呕吐Ⅰ度1例(4.76％);AST/ALT水平升高Ⅱ度1例(4.76％);皮疹Ⅰ度4例(19.04％)、Ⅱ度1例(4.76％);腹泻Ⅰ度2例(9.52％).结论 吉非替尼联合西黄丸可以显著改善晚期非小细胞肺癌本身及与治疗有关的热证或热毒证的症状,提高生存质量,延长生存时间,减轻毒副作用的发生率及程度,值得推广应用.

Efficacy evaluation of gefitinib combined with Xihuang pills in the treatment of advanced non-small cell lung cancer

Objective To evaluate the clinical efficacy of gefitinib combined with Xihuang Pills in the treatment of advanced non-small cell lung cancer.Methods Thirty-six patients with advanced non-small cell lung cancer treated in our hospital from September 2015 to December 2018 were selected as the research subjects.All patients received gefitinib combined with Xihuang Pills to observe the short-term efficacy of the patients.Results Among the 21 patients,10 had stable disease,8 had partial remission,3 had disease progression,zero had complete remission,the disease remission rate was 38.09%(8/21),and the disease control rate was 85.71%(18/21).None Progressive survival was 5 to 14(7.12±0.93)months,and overall survival was 6 to 24(10.23±1.10)months;nausea and vomiting occurred in 1 case(4.76%);AST/ALT level increasedⅡdegree 1 Cases(4.76%);4 cases of skin rash(19.04%),3 cases of skin rash(4.76%);2 cases of diarrhea(9.52%).Conclusion Gefitinib combined with Xihuang Pills can significantly improve the symptoms of heat syndrome or heat toxin syndrome caused by advanced non-small cell lung cancer itself and related to treatment,improve the quality of life,prolong survival time,and reduce the incidence and extent of toxic side effects.It is worthy of popularization and application.